Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Cash & Current Investments (2022 - 2025)

Oramed Pharmaceuticals' Cash & Current Investments history spans 4 years, with the latest figure at $56.9 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments changed N/A year-over-year to $56.9 million; the TTM value through Dec 2025 reached $56.9 million, changed N/A, while the annual FY2025 figure was $56.9 million, N/A changed from the prior year.
  • Cash & Current Investments reached $56.9 million in Q4 2025 per ORMP's latest filing, up from $4.9 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $154.3 million in Q3 2022 to a low of $4.9 million in Q3 2025.
  • Average Cash & Current Investments over 4 years is $85.5 million, with a median of $96.3 million recorded in 2024.
  • Peak YoY movement for Cash & Current Investments: crashed 94.61% in 2023, then soared 2098.65% in 2024.
  • A 4-year view of Cash & Current Investments shows it stood at $152.0 million in 2022, then crashed by 31.35% to $104.3 million in 2023, then dropped by 18.68% to $84.8 million in 2024, then plummeted by 32.91% to $56.9 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Cash & Current Investments are $56.9 million (Q4 2025), $4.9 million (Q3 2025), and $58.0 million (Q2 2025).